Rodman & Renshaw analyst Elemer Piros is grim about the prospects for obesity drugs over all, noting to the Wall Street Journal that the FDA wants a side effect profile on these drugs that is equivalent to diet and exercise. The bottom line: “This whole space is pretty much dead.”

Analysts take on obesity drugs turns grim after lorcaserin CRL – FierceBiotech